GlassScriptPhysician profile
Remi O Soile
NPI 1366510893
$12,294.54
in general payments reported to CMS, 2019-2025
38 companies · $1,855 in 2025
The $1,855 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,724 · 2020: $917 · 2021: $1,604 · 2022: $1,699 · 2023: $1,884 · 2024: $1,612 · 2025: $1,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,351.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,874.97 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $2,848.34 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Novo Nordisk INC | $1,137.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $713.75 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $550.53 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $466.34 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.94 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $400.17 | 2019-2023 | Xarelto |
| Abbvie INC. | $319.71 | 2022-2025 | |
| Pfizer INC. | $306.06 | 2019-2025 | |
| Amgen INC. | $282.31 | 2024-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $271.08 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $200.51 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Exact Sciences Corporation | $162.09 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $148.13 | 2021-2024 | Dexcom G6 Transmitter |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $148.09 | 2021-2023 | |
| Gilead Sciences, INC. | $146.72 | 2023-2025 | |
| Smith+Nephew, INC. | $139.73 | 2025 | Renasys Touch, Pico 7 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.08 | 2025 | Lifevest |
| Avanir Pharmaceuticals, INC. | $100.80 | 2019 | |
| Astellas Pharma US INC | $76.44 | 2024-2025 | Veozah |
| Sanofi Pasteur INC. | $68.76 | 2023 | |
| Indivior INC. | $46.82 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $45.22 | 2025 | Gemtesa |
| Abiomed | $45.19 | 2023 | Impella |
| Alnylam Pharmaceuticals INC. | $42.86 | 2023 | Givlaari |
| Shield Therapeutics INC | $26.53 | 2023-2024 | Accrufer |
| Corcept Therapeutics | $25.83 | 2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $25.13 | 2021 | |
| Corium, LLC | $22.47 | 2022 | |
| Inspire Medical Systems, INC. | $21.87 | 2023 | Inspire |
| Cmp Pharma, INC. | $18.14 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.54 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.26 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $15.44 | 2021 | |
| Allergan, INC. | $12.78 | 2020 | |
| Amarin Pharma, INC. | $12.61 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Remi Soile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.